# Islatravir and Methadone Pharmacokinetics (MK-8591-029)

> **NCT04568603** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 14 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Islatravir

## Key facts

- **NCT ID:** NCT04568603
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-16
- **Primary completion:** 2021-07-09
- **Final completion:** 2021-07-09
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04568603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04568603, "Islatravir and Methadone Pharmacokinetics (MK-8591-029)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04568603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*